论文部分内容阅读
将30例初诊断T2DM分为瑞格奈组和瑞格列奈联合重组甘精胰岛素组,治疗12周,观察FBG、2hPG、HbA1c变化比及血糖达标时间。结果联合重组甘精胰岛素组FBG、2hPG、HbA1c均优于瑞格列奈组,且血糖达标时间贪偏短。结论对T2DM病患者,瑞格列奈联合重组甘精岛素治疗效好地抑制血糖,改善胰岛素β细胞功能、C肽分泌改善。
30 cases of newly diagnosed T2DM were divided into two groups: regina group and repaglinide combined with recombinant glargine for 12 weeks. The changes of FBG, 2hPG and HbA1c and the time of reaching the blood glucose level were observed. Results The combined recombinant glargine group FBG, 2hPG, HbA1c were better than the repaglinide group, and blood glucose compliance time shorter. Conclusion In patients with T2DM, repaglinide combined with recombinant dendrinol effectively inhibits blood glucose, improves insulin β-cell function, and improves C-peptide secretion.